Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Abiraterone Acetate
/ administration & dosage
Aged
Aged, 80 and over
Androgen Antagonists
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Benzamides
/ administration & dosage
Follow-Up Studies
Humans
Male
Middle Aged
Nitriles
/ administration & dosage
Phenylthiohydantoin
/ administration & dosage
Prognosis
Prostatic Neoplasms, Castration-Resistant
/ drug therapy
Retrospective Studies
Survival Rate
Time Factors
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
16
10
2020
accepted:
27
01
2021
revised:
14
12
2020
pubmed:
20
2
2021
medline:
2
2
2022
entrez:
19
2
2021
Statut:
ppublish
Résumé
Our retrospective study aims to evaluate the prognostic role of duration of response to androgen deprivation therapy (ADT) in metastatic castration resistant prostate cancer (mCRPC) patients treated with enzalutamide (E) or abiraterone acetate (AA). Data about ADT start and duration were available in 255 (82%) of 311 patients treated with AA or E. Patients were divided in three groups according to ADT response (group 1 [G1]: <12 months; group 2 [G2]: 12-36 months; group 3 [G3]: >36 months). Outcome measures were progression-free survival (PFS) and overall survival (OS). Patients with longer ADT response had better OS (median 17.3 months G1, 19.9 months G2, 31.6 months G3; HR G3 vs G1 0.41, 95% CI 0.25-0.64; p = 0.001) and better PFS (median 5.9 months G1, 8.8 months G2, 11.7 months G3; HR G3 vs G1 0.41, 95% CI 0.41-0.27; p < 0001). In docetaxel-naive patients, median OS was 18.8 in G1, 35.2 in G2, and not reached in G3 (HR G3 vs G1 0.33, 95% CI 0.14-0.78; p = 0.038), median PFS was 7 months G1, 9.3 months G2, and 20 months G3 (HR G3 vs G1 0.31, 95% CI 0.15-0.62; p = 0.003). In postdocetaxel patients, median OS was 13.1 months in G1, 17.2 months in G2, and 21.4 months in G3 (HR G3 vs G1 0.52, 95% CI 0.29-0.94; p = 0.082), while median PFS was 5.2 months in G1, 6.8 months in G2, and 8.3 months in G3 (HR G3 vs G1 0.54, 95% CI 0.32-0.91; p = 0.067). Duration of ADT response is an independent prognostic factor of outcome with AA or E.
Sections du résumé
BACKGROUND
Our retrospective study aims to evaluate the prognostic role of duration of response to androgen deprivation therapy (ADT) in metastatic castration resistant prostate cancer (mCRPC) patients treated with enzalutamide (E) or abiraterone acetate (AA).
MATERIALS AND METHODS
Data about ADT start and duration were available in 255 (82%) of 311 patients treated with AA or E. Patients were divided in three groups according to ADT response (group 1 [G1]: <12 months; group 2 [G2]: 12-36 months; group 3 [G3]: >36 months). Outcome measures were progression-free survival (PFS) and overall survival (OS).
RESULTS
Patients with longer ADT response had better OS (median 17.3 months G1, 19.9 months G2, 31.6 months G3; HR G3 vs G1 0.41, 95% CI 0.25-0.64; p = 0.001) and better PFS (median 5.9 months G1, 8.8 months G2, 11.7 months G3; HR G3 vs G1 0.41, 95% CI 0.41-0.27; p < 0001). In docetaxel-naive patients, median OS was 18.8 in G1, 35.2 in G2, and not reached in G3 (HR G3 vs G1 0.33, 95% CI 0.14-0.78; p = 0.038), median PFS was 7 months G1, 9.3 months G2, and 20 months G3 (HR G3 vs G1 0.31, 95% CI 0.15-0.62; p = 0.003). In postdocetaxel patients, median OS was 13.1 months in G1, 17.2 months in G2, and 21.4 months in G3 (HR G3 vs G1 0.52, 95% CI 0.29-0.94; p = 0.082), while median PFS was 5.2 months in G1, 6.8 months in G2, and 8.3 months in G3 (HR G3 vs G1 0.54, 95% CI 0.32-0.91; p = 0.067).
CONCLUSIONS
Duration of ADT response is an independent prognostic factor of outcome with AA or E.
Identifiants
pubmed: 33603237
doi: 10.1038/s41391-021-00336-1
pii: 10.1038/s41391-021-00336-1
doi:
Substances chimiques
Androgen Antagonists
0
Benzamides
0
Nitriles
0
Phenylthiohydantoin
2010-15-3
enzalutamide
93T0T9GKNU
Abiraterone Acetate
EM5OCB9YJ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
812-825Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature.
Références
Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22:232–40. https://doi.org/10.3322/canjclin.22.4.232 .
doi: 10.3322/canjclin.22.4.232
pubmed: 4625049
Tucci M, Scagliotti GV, Vignani F. Metastatic castration-resistant prostate: time for innovation. Future Oncol. 2015;11:91–106. https://doi.org/10.2217/fon.14.145 .
doi: 10.2217/fon.14.145
pubmed: 25572785
Fizazi K, Scher HI, Molina A, Logothetis C, Chi K, Jones R, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983–92. https://doi.org/10.1016/S1470-2045(12)70379-0 .
doi: 10.1016/S1470-2045(12)70379-0
pubmed: 22995653
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg C, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60. https://doi.org/10.1016/S1470-2045(14)71205-7 .
doi: 10.1016/S1470-2045(14)71205-7
pubmed: 25601341
Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg C, Higano C, et al. Enzalutamide in Men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL Study. Eur Urol. 2017;71:151–4. https://doi.org/10.1016/j.eururo.2016.07.032 .
doi: 10.1016/j.eururo.2016.07.032
pubmed: 27477525
Scher HI, Fizazi K, Saad F, Taplin M, Sternberg C, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2017;367:1187–97. https://doi.org/10.1056/NEJMoa1207506 .
doi: 10.1056/NEJMoa1207506
Berry WR, Laszlo J, Cox E, Paulson D. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer. 1979;44:763–75.
doi: 10.1002/1097-0142(197908)44:2<763::AID-CNCR2820440251>3.0.CO;2-5
Kantoff W, Halabi S, Conaway M, PIcus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone- refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506–13. https://doi.org/10.1200/JCO.1999.17.8.2506 .
doi: 10.1200/JCO.1999.17.8.2506
pubmed: 10561316
Halabi S, Small E, Kantoff PW, Kattan MW, Kaplan E, Dawson N, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232–7.
doi: 10.1200/JCO.2003.06.100
Halabi S, Kub CY, Kelly WK, Fizazi K, Moul J, Kaplan E, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32:671–7. https://doi.org/10.1200/JCO.2013.52.3696 .
doi: 10.1200/JCO.2013.52.3696
pubmed: 24449231
pmcid: 3927736
Smaletz O, Scher HI, Small EJ, Verbel D, McMillan A, Reganet K, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20:3972–82. https://doi.org/10.1200/JCO.2002.11.021 .
doi: 10.1200/JCO.2002.11.021
pubmed: 12351594
Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock I, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007;13:6396–403. https://doi.org/10.1158/1078-0432.CCR-07-1036 .
doi: 10.1158/1078-0432.CCR-07-1036
pubmed: 17975152
Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2010;16:203–11. https://doi.org/10.1158/1078-0432.CCR-09-2514 .
doi: 10.1158/1078-0432.CCR-09-2514
pubmed: 20008841
Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan E, Petrylak D, et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013;105:1729–37. https://doi.org/10.1093/jnci/djt280 .
doi: 10.1093/jnci/djt280
pubmed: 24136890
pmcid: 3833929
Armstrong AJ, Lin P, Higano CS, Sternberg C, Sonpavde G, Tombal B, et al. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Ann Oncol. 29;2200–7. https://doi.org/10.1093/annonc/mdy406 .
Armstrong AJ, Lin P, Tombal B, Rosbrook B, van Os S, Beer T. et al. Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer from the PREVAIL Trial. Eur Urol.2020;78:347–57. https://doi.org/10.1016/j.eururo.2020.04.061 .
doi: 10.1016/j.eururo.2020.04.061
pubmed: 32527692
Giacinti S, Crlini P, Roberto M, Bassanelli M, Strigari L, Pavese F, et al. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate. Anticancer Drugs. 2017;28:110–5. https://doi.org/10.1097/CAD.0000000000000434 .
doi: 10.1097/CAD.0000000000000434
pubmed: 27763885
Loriot Y, Eymard JC, Patrikidou A, Ileana E, Massard C, Albiges L, et al. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. Eur J Cancer. 2015;51:1946–52. https://doi.org/10.1016/j.ejca.2015.06.128 .
doi: 10.1016/j.ejca.2015.06.128
pubmed: 26208462
McKay RR, Werner L, Fiorillo M, Nakabayashy M, Kantoff PW, Taplin M. Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2016;19:398–405. https://doi.org/10.1038/pcan.2016.31 .
doi: 10.1038/pcan.2016.31
pubmed: 27502737
pmcid: 6034654
Oudard S, Kheoh TS, Yu M, Smith M, Small E, Mulders FA, et al. Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): results from COU-AA-302. J Clin Oncol. 2017;32:14–14. https://doi.org/10.1016/j.eururo.2015.10.021 .
doi: 10.1016/j.eururo.2015.10.021
Nakabayashi M, Werner L, Oh WK, Regan MM, Kantoff PW, Taplin ME. Secondary hormonal therapy in men with castration-resistant prostate cancer. Clin Genitourin Cancer. 2011;9:95–103. https://doi.org/10.1016/j.clgc.2011.06.006 .
doi: 10.1016/j.clgc.2011.06.006
pubmed: 21958520
Li JR, Chiu KY, Wang SS, Yang CK, Chen CS, Ho HC, et al. Effectiveness of deferred combined androgen blockade therapy predicts efficacy in abiraterone acetate treated metastatic castration-resistant prostate cancer patients after docetaxel. Front Pharm. 2017;8:836. https://doi.org/10.3389/fphar.2017.00836 .
doi: 10.3389/fphar.2017.00836
Davies RS, Smith C, Frazer RD, Button MR, Tanguay J, Barber J, et al. What predicts minimal response to abiraterone in metastatic castrate-resistant prostate cancer? Anticancer Res. 2015;35:5615–21.
pubmed: 26408734
Afshar M, Al-Alloosh F, Pirrie S, Rowan C, James N, Porfiri E. Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer. Anticancer Res. 2015;35:1057–63.
pubmed: 25667494
Hung J, Taylor AR, Divine GW, Hafron J, Hwanh C. The effect of time to castration resistance on outcomes with abiraterone and enzalutamide in metastatic prostate cancer. Clin Genitourin Cancer. 2016;14:381–8. https://doi.org/10.1016/j.clgc.2016.03.021 .
doi: 10.1016/j.clgc.2016.03.021
pubmed: 27157640
Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman I, True L, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007;67:5033–41. https://doi.org/10.1158/0008-5472.CAN-06-3332 .
doi: 10.1158/0008-5472.CAN-06-3332
pubmed: 17510436
Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA. et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008;68:6407–15. https://doi.org/10.1158/0008-5472.CAN-07-5997 .
doi: 10.1158/0008-5472.CAN-07-5997
pubmed: 18676866
Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007;28:778–808. https://doi.org/10.1210/er.2007-0019 .
doi: 10.1210/er.2007-0019
pubmed: 17940184
Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock I. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242–5. https://doi.org/10.1200/JCO.2007.12.4008 .
doi: 10.1200/JCO.2007.12.4008
pubmed: 18182665
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kodak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54. https://doi.org/10.1016/S0140-6736(10)61389-X .
doi: 10.1016/S0140-6736(10)61389-X
pubmed: 20888992
Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23. https://doi.org/10.1056/NEJMoa1213755 .
doi: 10.1056/NEJMoa1213755
pubmed: 23863050
Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D. et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2014;25:657–62. https://doi.org/10.1093/annonc/mdt581 .
doi: 10.1093/annonc/mdt581
pubmed: 24458472
pmcid: 4433513
Boegemann M, Schlack K, Früchtenicht L, Steinestel J, Schrader AJ, Wennmann Y, et al. A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting. Oncotarget. 2019;10:5082–91.
doi: 10.18632/oncotarget.27133
Chi KN, Kheoh T, Ryan CJ, Molina A, Bellmunt J, Vogelzang NJ, et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol. 2016;27:454–60. https://doi.org/10.1093/annonc/mdv594 .
doi: 10.1093/annonc/mdv594
pubmed: 26685010
Ryan C, Kheoh T, Li J, Molina A, De Porre P, Carles J, et al. Prognostic index model for progression-free survival in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with abiraterone acetate plus prednisone. Clin Genitourin Cancer. 1:72–7.e1.
Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M, et al. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and in castration resistant prostate. Cancer Treat Rev. 2015;41:884–92. https://doi.org/10.1016/j.ctrv.2015.08.002 .
doi: 10.1016/j.ctrv.2015.08.002
pubmed: 26342718
Chen CD, Welsbie DS, Tran C, Baek S, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33–9. https://doi.org/10.1038/nm972 .
doi: 10.1038/nm972
pubmed: 14702632
Stanbrough M, Bubley GJ, Ross K, Golub T, Rubin M, Penning T, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent. Cancer Res. 2006;66:2815–25. https://doi.org/10.1158/0008-5472.CAN-05-4000 .
doi: 10.1158/0008-5472.CAN-05-4000
pubmed: 16510604
Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69:16–22. https://doi.org/10.1158/0008-5472.CAN-08-2764 .
doi: 10.1158/0008-5472.CAN-08-2764
pubmed: 19117982
pmcid: 2614301
Yin L, Hu Q. CYP17 inhibitors-, C17,20-lyase inhibitors and multi-targeting agents. Nat Rev Urol. 2014;11:32–42. https://doi.org/10.1038/nrurol.2013.274 .
doi: 10.1038/nrurol.2013.274
pubmed: 24276076
Darshan MS, Loftus MS, Thadani-Mulero M, Levy B, Escuin D, Zhou XK, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011;71:6019–29. https://doi.org/10.1158/0008-5472.CAN-11-1417 .
doi: 10.1158/0008-5472.CAN-11-1417
pubmed: 21799031
pmcid: 3354631
Thadani-Mulero M, Nanus DM, Giannakakou P. Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res. 2012;72:4611–5. https://doi.org/10.1158/0008-5472.CAN-12-0783 .
doi: 10.1158/0008-5472.CAN-12-0783
pubmed: 22987486
pmcid: 3448065
Jiang J, Huang H. Targeting the androgen receptor by taxol in castration-resistant prostate cancer. Mol Cell Pharm. 2010;2:1–5.
Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu, Thompson E, et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. 2012;23:2943–7. https://doi.org/10.1093/annonc/mds119 .
doi: 10.1093/annonc/mds119
pubmed: 22771826